| abstract |
Provided are compounds that modulate glucagon-like peptide 1 (GLP-1 ) receptors, methods for their synthesis, and methods for their therapeutic and/or prophylactic use. Such compounds may themselves act as modulators or potentiators of the GLP-1 receptor, or act on incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or on Peptide-based therapies such as exenatide and liraglutide function and have the following structures (where Indicates one or both of R-type and S-type compounds): wherein A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein. |